Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Eisai Co., Ltd. (4523:JPX), powered by AI.
Eisai Co., Ltd. is currently trading at ¥3,829. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Eisai Co., Ltd. on Alpha Lenz.
Eisai Co., Ltd.'s P/E ratio is 23.4.
“Eisai Co., Ltd. trades at a P/E of 23.4 (fair value) with modest ROE of 5.4%.”
Ask for details →Eisai Co., Ltd. is a prominent Japanese pharmaceutical company engaged in the research, development, manufacture, and marketing of healthcare products. Known for its significant contributions to drug discovery and development, Eisai primarily focuses on therapeutic areas such as oncology, neurology, and gastrointestinal diseases. The company is renowned for developing Aricept, a leading treatment for Alzheimer's disease, showcasing its expertise in neurology. Eisai's operations extend across multiple sectors in healthcare, with a strong emphasis on innovation and patient-centric solutions. Its business model integrates cutting-edge research with robust clinical development through global partnerships and collaborations. By leveraging biopharmaceutical advancements, Eisai aims to address unmet medical needs and improve patient outcomes internationally. In the financial markets, Eisai Co., Ltd. plays a crucial role as a major player in the pharmaceutical industry, contributing to advancements in medical research and treatment options. Its commitment to research excellence and strategic global expansion underscores its status as a leader in the healthcare sector, impacting both local and international markets with its future-focused therapeutic developments.
“Eisai Co., Ltd. trades at a P/E of 23.4 (fair value) with modest ROE of 5.4%.”
Ask for details →Eisai Co., Ltd. (ticker: 4523) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 10,917 employees. Market cap is $1.1T.
The current price is 3,829 with a P/E ratio of 23.38x and P/B of 1.29x.
ROE is 5.41% and operating margin is 6.89%. Annual revenue is $789.4B.